| abstract |
It refers to an optionally fused heterocyclyl derivative of pyrimidine of formula (I) or the salts, hydrates, solvates, polymorphs and stereoisomers thereof, where: Y is NR or O; R is H or optionally substituted C1-C4 alkyl; R1 is H, -OH, among others; R2 is H, halogen, among others; R3a is optionally substituted C1-C6 alkyl, C1-C6 alkoxy, among others; R3b and R3c are H, -CN, among others or combine to form an oxo group; R4a is H, halogen, among others; R4b is H, oxo, among others; R5 is (CR8R9) pOR12, among others; n and p are integers from 0 to 4; R6a and R6b are H, halogen, C1-C6 alkyl, among others; R8, R9 and R12 are H, optionally substituted C1-C6 alkyl, among others; B is a ring system such as aryl, heteroaryl, among others. It is a selected compound: N6-cyclopropyl-5-fluoro-N4 - [[4- (1H-tetrazol-5-ylmethyl) phenyl] methyl] -N6 - [[4- (trifluoromethyl) phenyl] methyl] pyrimidine-4, 6-diamine; among others. It also refers to a composition. These compounds modulate the activity of an orphan receptor related to the retinoic acid receptor (ROR). This compound is useful in the treatment of inflammatory, metabolic and autoimmune diseases. |